Showing results (131-140 of 167) with videos related to

Sort By:
Pageof 17
Lancet (London, England)|June 10, 2017
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trialsKristian Reich, Kim A Papp, Andrew Blauvelt, et al.
The Journal of Investigative Dermatology. Symposium Proceedings|August 5, 2003
Morphological approach to hair disordersRodney Sinclair, Damian Jolley, Rica Mallari, et al.
American Journal of Clinical Dermatology|January 23, 2024
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial ProgramBrett King, Jennifer Soung, Christos Tziotzios, et al.
The Journal of Dermatological Treatment|August 7, 2026
Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REALRaj Chovatiya, Matthew Zirwas, Melinda J Gooderham, et al.
Frontiers in Medicine|August 5, 2021
Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled TrialJohn McCoy, Andy Goren, Flávio Adsuara Cadegiani, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|March 19, 2019
Platelet-Rich Plasma as a Treatment for Androgenetic AlopeciaAditya K Gupta, John Cole, David P Deutsch, et al.
The New England Journal of Medicine|March 25, 2022
Two Phase 3 Trials of Baricitinib for Alopecia AreataBrett King, Manabu Ohyama, Ohsang Kwon, et al.
Journal of the American Academy of Dermatology|October 18, 2024
Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trialMelissa Piliang, Charles Lynde, Brett King, et al.
Lancet (London, England)|July 27, 2020
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialEric L Simpson, Rodney Sinclair, Seth Forman, et al.
Immunotherapy|July 5, 2023
A plain language summary on ritlecitinib treatment for adults and adolescents with alopecia areataBrett King, Xingqi Zhang, Walter Gubelin Harcha, et al.
Pageof 17